首页AIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年6月info | 年同比变化 |
|---|---|---|
收入 | 2.50万 | -50.00% |
经营支出 | 266.10万 | -28.77% |
净收入 | -279.40万 | -52.18% |
净利润率 | -1.12万 | -204.36% |
每股收益 | -3.68 | -22.67% |
息税折旧摊销前利润 | -259.10万 | 28.68% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2025年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 83.50万 | -91.70% |
总资产 | 412.90万 | -73.73% |
负债总额 | 1067.50万 | 11.05% |
权益总额 | -654.60万 | — |
发行在外的股份 | 270.87万 | — |
市净率 | -0.30 | — |
资产回报率 | -127.49% | — |
资本回报率 | 260.64% | — |
现金流
现金净变动
| (USD) | 2025年6月info | 年同比变化 |
|---|---|---|
净收入 | -279.40万 | -52.18% |
来自运营的现金 | -153.10万 | 49.10% |
投资现金 | 75.40万 | -8.72% |
融资现金 | 35.50万 | -85.46% |
现金净变动 | -42.20万 | -262.93% |
自由现金流 | -136.59万 | 65.91% |
简介
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
成立时间
1966
员工数量
22
